Drug intelligence / Profile preview

AL-704

Development stage: Discontinued
Lead developer: Johnson & Johnson
Modality: Small Molecules
Administration: Oral

Overview

AL-704 is an investigational small molecule drug that functions as an inhibitor of the hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase. This enzyme is essential for viral replication in HCV, and its inhibition disrupts the ability of the virus to reproduce. AL-704 was initially developed by Johnson & Johnson and Alios Biopharma for the treatment of chronic hepatitis C infection. The drug underwent Phase 1 clinical trials to assess safety, tolerability, and pharmacokinetics in both healthy volunteers and patients with chronic hepatitis C. Despite early development efforts, further advancement was discontinued after Phase 1[1][3][6].

Targets

NS5B (Hepatitis C virus non-structural protein 5B (NS5B) RNA-dependent RNA polymerase)

Beyond the preview

Go deeper on AL-704.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AL-704.

Explore the full profile